Flumazenil may be beneficial for some patients with treatment-refractory sleepiness

A new study in the October 15 issue of the Journal of Clinical Sleep Medicine demonstrates that sublingual and transdermal flumazenil may be beneficial to patients with treatment-refractory hypersomnolence. In an analysis of 153 patients, flumazenil provided sustained clinical benefits to 39% of patients.

Read the study in JCSM: Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients